Pharmacology & Therapeutics

Lithium toxicity

Lithium is cleared by the kidney alongside sodium, so volume depletion, renal impairment or a drug that blocks its elimination turns an unchanged dose into rising concentrations and neurotoxicity.

In a nutshell

Lithium toxicity is accumulation from reduced renal clearance, usually after dehydration, vomiting, diarrhoea, acute kidney injury or an interacting NSAID, angiotensin converting enzyme (ACE) inhibitor or thiazide. Stop lithium, give intravenous sodium chloride 0.9%, and record the time of the last dose: monitoring levels are drawn 12 hours post dose.

Classic presentation

A woman on long-term lithium has two days of vomiting and diarrhoea, and now has a coarse tremor, ataxia, slurred speech and confusion.

Key points

  • Lithium is prescribed by brand and formulation. Priadel prolonged-release is the usual UK choice, and any switch needs the same monitoring as starting lithium.
  • Chronic toxicity is dangerous at a lower number than acute: the brain is already loaded, so neurotoxicity appears while the serum concentration still looks unremarkable.
  • Thiazides can raise the level fast. Theophylline, acetazolamide and sodium bicarbonate products lower it, as do sodium-glucose co-transporter 2 (SGLT-2) inhibitors.
  • Antipsychotics, verapamil, diltiazem, carbamazepine, selective serotonin reuptake inhibitors (SSRIs) and triptans raise neurotoxicity risk without necessarily raising the level.
  • Dehydration and low-sodium diets are BNF contra-indications to lithium, not merely cautions.
  • Persistent deficits are called SILENT, the syndrome of irreversible lithium-effectuated neurotoxicity. A 2024 review of 117 cases found cerebellar dysfunction in 77%.
  • Lithium causes hypothyroidism, hypercalcaemia through the parathyroid glands, and nephrogenic diabetes insipidus that may not reverse after stopping.
  • NICE CG185 governs lithium prescribing and monitoring. TOXBASE governs toxicity management, and it needs a professional login.

First-line investigation

Urgent serum lithium with the time of the last dose recorded, alongside U&E, creatinine and eGFR, calcium, thyroid function, glucose and an ECG.

Management

Stop lithium and stabilise

  • Withhold lithium immediately, assess A to E (airway, breathing, circulation, disability, exposure), and phone the National Poisons Information Service (NPIS) on 0344 892 0111.10,3,7
  • Send an urgent serum lithium and write the time of the last dose on the form, with U&E, creatinine and eGFR, calcium, thyroid function, glucose and an ECG.1,2

Read the level against the clock

  • Monitoring levels are taken 12 hours post dose; in twice-daily dosing the morning dose is withheld until the sample is drawn. In toxicity, take it now and repeat.1,2
  • NHS Lanarkshire defines toxicity as any level above 1.2 mmol/L; Royal Cornwall expects toxic effects above 1.5 mmol/L. Both say toxicity occurs within the normal range.3,2
  • Usual targets: 0.6 to 0.8 mmol/L in bipolar disorder, and 0.4 to 0.6 mmol/L in recurrent major depressive disorder and initially at 65 years and over.1,8
  • Peak effects can be delayed up to 24 hours, especially in someone not on regular lithium, so one falling result does not end observation.2,4

Restore clearance, and what does not work

  • Give sodium chloride 0.9% IV even if euvolaemic. If hypovolaemic without overload risk, give 500 mL isotonic crystalloid over under 15 minutes, then reassess; otherwise NPIS sets the replacement plan.4,2,11,10
  • There is no antidote, and activated charcoal does not adsorb lithium, a small inorganic cation with nothing for charcoal to bind.5,2,4
  • Recurrent or prolonged seizures: lorazepam 4 mg by slow intravenous injection into a large vein, repeated once after 5 to 10 minutes if needed. Do not use phenytoin.12,5

Haemodialysis, and the numbers behind it

  • Extracorporeal Treatments in Poisoning (EXTRIP) recommends dialysis if kidney function is impaired and lithium exceeds 4.0 mmol/L, or for reduced consciousness, seizures or life-threatening dysrhythmia at any level.6,4
  • It suggests dialysis above 5.0 mmol/L, for confusion, or when the predicted time to reach below 1.0 mmol/L with optimal management exceeds 36 hours.6
  • Intermittent haemodialysis is preferred. Stop below 1.0 mmol/L or on clear clinical improvement, or after at least 6 hours if no level is available.6
  • Take serial levels over the 12 hours after stopping: lithium redistributing out of tissue can push the level back up and need another session.6

The monitoring schedule, which is your job

  • Level 1 week after starting lithium and 1 week after every dose or formulation change, then weekly until stable.1,13
  • Once stable, every 3 months for the first year, then every 6 months. Stay 3-monthly at 65 or over, on interacting drugs, or if the last level was 0.8 mmol/L or higher.1,8
  • Weight or BMI, renal and thyroid function, and U&E including calcium at least every 6 months. Extra levels for intercurrent illness, sodium or fluid changes, or toxicity signs.1,4
  • Sick-day rule: vomiting, diarrhoea, fever or heavy sweating means urgent medical advice and a level. Issue the lithium treatment pack: booklet, alert card and record book.1,7
  • Do not restart lithium after toxicity without specialist review. Stopping for good needs a taper over at least 4 weeks, preferably up to 3 months, then relapse monitoring for 3 months.1,5

Exam traps

  • A lithium level without a sampling time is uninterpretable. Ask when the last dose was taken before you interpret any number.
  • Fine tremor is a therapeutic adverse effect. Coarse tremor, ataxia, dysarthria and myoclonus are toxicity.
  • Activated charcoal is the reflex answer in overdose and the wrong one here: lithium is an inorganic ion with nothing for charcoal to bind.
  • Severe neurotoxicity, seizure or life-threatening dysrhythmia is an indication for dialysis whatever the concentration. Do not wait for a number above 4.0 mmol/L.
  • A falling level after dialysis is not the end. Lithium redistributes out of tissue, so levels are repeated over the next 12 hours.
  • The UK severity bands are symptom bands, not concentration bands, and UK sources do not even agree on where toxicity begins.
  • Do not add a thiazide, NSAID or ACE inhibitor for a patient on lithium without planning a level. They raise it by reducing renal elimination.

Illustrations

Proximal tubular handling of lithium and sodiumDiagram showing renal sodium and lithium handling and how dehydration, renal impairment and interacting medicines reduce lithium clearance.PassFinals · original
Dose-response spectrum of lithium neurotoxicityGraphic progressing from gastrointestinal symptoms and worsening tremor to ataxia, dysarthria, confusion, seizures and coma, with a warning that serum levels correlate imperfectly with clinical severity.PassFinals · original

Key sources

  1. BNF: Lithium carbonate (Sections used: Monitoring requirements, therapeutic drug monitoring, for the 12-hour post-dose sampling rule, the withheld morning dose in twice-daily regimens, the 1 week after initiation and after each dose or formulation change then weekly until stable schedule, the target ranges of 0.6 to 0.8 mmol/litre (bipolar disorder, lithium-naive), 0.4 to 0.6 mmol/litre (recurrent major depressive disorder, and initially at 65 years and over), 0.8 to 1 mmol/litre and 0.6 to 0.8 mmol/litre where the effect is sub-optimal, the every 3 months for the first year then every 6 months rule, the six higher-risk groups monitored 3-monthly including a last concentration of 0.8 mmol/litre or higher, and the three triggers for additional monitoring. Monitoring of patient parameters for the baseline panel and the 6-monthly physical checks. Contra-indications for dehydration and low sodium diets. Treatment cessation for the taper of at least 4 weeks, preferably up to 3 months, with relapse monitoring for 3 months. Patient and carer advice for the lithium treatment pack and fluid and salt counselling. Side-effects, further information, Overdose, for the signs of intoxication. bnf.nice.org.uk returns an empty body to automated fetching; this text is the verbatim extract in reports/textbook-source-packs/batch06/lithium-carbonate.md, retrieved live on 2026-08-07. The BNF gives no toxicity-management dose for lithium: it cross-refers to a separate Emergency treatment of poisoning summary, which was not captured and is not cited here.)
  2. Royal Cornwall Hospitals NHS Trust: Lithium Clinical Guideline V5.0, approved November 2025, valid January 2026 to January 2029 (A single-trust guideline, written to comply with the National Patient Safety Agency 2009 alert PSA005 Safer Lithium Therapy. Sections used: 2.4.1 (dose usually adjusted to 0.6 to 0.8 mmol/L, with the trust's own note that this range varies between sources, and that targets are patient-specific and recorded in the purple lithium record booklet); 2.4.2 (levels 10 to 14 hours, ideally 12, after the night-time dose); 2.4.3 (monitoring on admission, weekly after a dose change or new interacting drug until stable, then monthly, then at least 3-monthly); 2.6.1 (toxic effects expected above 1.5 mmol/L, although they can occur at lower concentrations); 2.7.1 (onset may be delayed, peak effects not occurring for as long as 24 hours, especially in patients not receiving chronic lithium); 2.7.2 to 2.7.4 (the mild, moderate and severe symptom lists, which are symptom bands and not concentration bands); 2.8.1 (there is no specific antidote for lithium); 2.9.1, 2.9.2 and 2.9.5 (the interaction lists by mechanism, including dapagliflozin, added at V5.0).)Published 1 Nov 2025
  3. NHS Lanarkshire: Standard Operating Procedure for Initiation, Prescribing and Monitoring of Lithium, v1.1, approved 18 March 2026, review March 2029 (Hosted on the NHS Scotland Right Decisions platform. Sections used: Advice regarding doses and lithium target levels (0.6 to 0.8 mmol/l suitable for most people prescribed lithium for the first time; lower doses and lower targets in older, frail, low-body-weight patients and in mild to moderate renal impairment; 0.8 to 1.0 mmol/l for people who have relapsed on lithium; and the trust definition that lithium toxicity is any level greater than 1.2 mmol per litre, with the caveat that toxic effects may develop within the normal range especially in older patients). Appendix 3 for the interaction lists split by mechanism. Appendix 4 for the toxicity symptom list, the three commonest causes of toxicity, and the instruction that a lithium level should be checked urgently and lithium suspended if there are signs and symptoms of toxicity.)Published 18 Mar 2026
  4. NHS Lothian: Lithium Handbook v1.1, effective 2 January 2023 (A single-board handbook whose stated review date of 2 January 2026 has passed, so it is cited as UK application of EXTRIP rather than as current authority. Sections used: 3.1 (distribution half-life of 18 to 30 hours; samples approximately 12 hours post dose); 4.1 (the acute, chronic and acute-on-chronic distinction, and the statement that symptoms do not correlate with serum lithium levels); 4.2 (activated charcoal does not prevent the absorption of lithium; there is no specific antidote; serial concentrations because absorption and distribution are slow; intravenous fluids to increase renal lithium elimination even when euvolaemic; and the haemodialysis thresholds of severe symptoms irrespective of concentration or a concentration above 5 mmol/L, and above 4 mmol/L in impaired kidney function, older adults, low muscle mass, or a doubling of baseline serum creatinine).)Published 2 Jan 2023
  5. Royal College of Emergency Medicine and National Poisons Information Service: Management of Patients with Suspected but Unidentified Poisoning in the Emergency Department, April 2025 (Locators used: Table 5, page 15, Poisons poorly adsorbed by activated charcoal or for which it is not recommended, which lists Lithium alongside boric acid, cyanide, ethanol, ethylene glycol, iron, lead, malathion, methanol, mercury, hydrocarbons and strong acids and alkalis. Page 15 also carries the single-dose activated charcoal rule (consider it only for a substance known to be bound by charcoal ingested within the last hour) and the statement that renal replacement therapy, whole bowel irrigation, multidose activated charcoal and urine alkalinisation are agent specific and should be initiated following TOXBASE or NPIS advice. Page 12 for recurrent or prolonged seizures, where benzodiazepines are recommended for initial management and phenytoin should not be used because it causes sodium channel blockade. Summary recommendation 8, page 2, for the discharge criteria and for taking the observation period from TOXBASE-specific information.)Published 1 Apr 2025
  6. EXTRIP (Extracorporeal Treatments in Poisoning) Workgroup: lithium recommendations (The graded recommendations in full. Extracorporeal treatment is recommended in severe lithium poisoning (1D); if kidney function is impaired and the lithium concentration is above 4.0 mEq/L (1D); and for a decreased level of consciousness, seizures or life-threatening dysrhythmias irrespective of the concentration (1D). It is suggested above 5.0 mEq/L (2D), for confusion (2D), and if the expected time to reach below 1.0 mEq/L with optimal management is more than 36 hours (2D). Cessation when the concentration is below 1.0 mEq/L or clinical improvement is apparent (1D), or after a minimum of 6 hours if the concentration is not readily available (1D). After interruption, serial concentrations over 12 hours to decide on further sessions (1D). Intermittent haemodialysis is the preferred modality, with continuous renal replacement therapy an acceptable alternative (1D). EXTRIP writes mEq/L; lithium is monovalent, so mEq/L and mmol/L are numerically identical and this chapter uses mmol/L throughout. Dargan (Guy's and St Thomas') is a co-author.)
  7. NHS: Side effects of lithium (Patient-facing NHS emergency advice, page last reviewed 9 August 2023. The Serious side effects section lists the symptoms that mean call 999 or go to A&E now (stomach ache with nausea and diarrhoea, blurred vision, thirst with polyuria and incontinence, lightheadedness or drowsiness, confusion and blackouts, shaking, muscle weakness, twitches and jerks, and difficulty speaking), states that these are signs of lithium toxicity and that lithium should be stopped straight away, and gives the How to avoid high lithium levels advice on blood tests, not reducing salt intake suddenly, keeping fluid intake up in hot weather and exercise, alcohol, and telling any doctor or pharmacist about lithium before any new medicine.)Published 14 Aug 2023 | Updated 1 Oct 2024
  8. NICE QS95: Bipolar disorder in adults, quality statement 5, maintaining plasma lithium levels (Used for the maintenance range and its rationale, verbatim: plasma lithium levels below 0.6 mmol per litre are ineffective and levels above 0.8 mmol per litre are linked to increased toxicity, so once lithium has been started and stabilised levels need to be maintained within 0.6 to 0.8 mmol per litre; and if a patient needs levels maintained above 0.8 mmol per litre they should be monitored at least every 3 months. This page's own Source guidance line attributes those statements to NICE guideline CG185 (2014, updated 2023), recommendations 1.10.15 and 1.10.19 on the Source guidance line, and 1.10.20 in the Definitions block. Those recommendation numbers are quoted here as they appear on this page; the CG185 Recommendations chapter itself could not be rendered (see the CG185 reference).)
  9. Konieczny K, Detraux J, Bouckaert F. The Syndrome of Irreversible Lithium-Effectuated Neurotoxicity: A Scoping Review. Alpha Psychiatry 2024;25(2):190-205 (Non-UK scoping review, cited only for the name of the syndrome and the pattern of persistent deficits. The PubMed abstract states that 91 articles were reviewed and information extracted from 117 cases of SILENT; that the prevailing outcome was persistent cerebellar dysfunction in 77% of cases; that other common sequelae were cognitive problems, parkinsonism, choreoathetosis, tardive dyskinesia and peripheral neuropathy; and that the commonest acute neurological feature was an altered level of consciousness (61.4%). The PubMed Central full text returns a reCAPTCHA challenge to automated fetching, so only the abstract was read and no figure beyond those above is cited. No duration threshold for calling a deficit persistent is given in the abstract, so none is stated in this chapter.)Published 1 Mar 2024
  10. TOXBASE and the UK National Poisons Information Service (NPIS) (The primary UK clinical toxicology database, and the document that actually governs lithium toxicity management. Its public page states that TOXBASE is for registered health professionals only and gives the UK NPIS telephone number 0344 892 0111. The database itself sits behind a login and was not consulted for this chapter; nothing here rests on it except the contact route. The NPIS descriptive page at https://www.npis.org/Toxbase.html is readable and confirms that TOXBASE is coordinated by NPIS Edinburgh, is commissioned by the UK Health Security Agency, carries over 21,000 monographs and is not available for public access, but it contains no clinical content and no telephone number.)
  11. NICE CG174: Intravenous fluid therapy in adults in hospital (Recommendation 1.3.1: when adult intravenous fluid resuscitation is required, use a crystalloid containing sodium 130 to 154 mmol/litre, 500 mL over less than 15 minutes, then reassess. This is a general hypovolaemia regimen, not a lithium-specific clearance rate.)Published 10 Dec 2013 | Updated 5 May 2017
  12. BNF: Lorazepam (Indications and dose, under Status epilepticus, febrile convulsions, convulsions caused by poisoning: adult, by slow intravenous injection, 4 mg for 1 dose, then 4 mg for 1 dose to be given 5 to 10 minutes after the first dose if required. Directions for administration: for slow intravenous injection the solution should preferably be diluted with an equal volume of water for injections or sodium chloride 0.9%, and given into a large vein. bnf.nice.org.uk returns an empty body to automated fetching; this text is the verbatim extract in reports/textbook-source-packs/batch06/lorazepam.md, retrieved live on 2026-08-07.)
  13. NICE CG185: Bipolar disorder, assessment and management (The governing NICE guideline for lithium prescribing and monitoring. The guidance page declares Last reviewed: 30 July 2024, and the Update information chapter at https://www.nice.org.uk/guidance/cg185/chapter/Update-information lists December 2023 as the most recent recommendation change and October 2024 as the most recent minor change. Both were opened on 2026-08-07. No September 2025 update is recorded at NICE, so the label previously carried by this chapter has been corrected. The Recommendations chapter returned an empty body on every URL variant tried, so no recommendation locator is printed against this reference; the CG185 recommendation numbers this chapter relies on are quoted from NICE QS95, which is cited separately and carries them on its own page.)Published 24 Sept 2014

This page is exam revision material, not medical advice, and must not be used for patient care. Always check drug doses against the BNF and current guidance. Full disclaimer.